Paradia, Dorotea C.

HRN: 03-48-74  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/05/2025
CEFTRIAXONE 1G (VIAL)
02/05/2025
02/19/2025
IV
2 Grams
OD
Burn Injury
Waiting Final Action 
02/05/2025
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
02/05/2025
02/12/2025
TOPICAL
Apply Generously
OD
Burn Injury
Waiting Final Action 
02/05/2025
AZITHROMYCIN 500MG TABLET (TAB)
02/05/2025
02/10/2025
ORAL
500mg
BID
Pneumonia Sec To Inhalation Injury
Waiting Final Action 
02/13/2025
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
02/13/2025
02/13/2025
IV
4.5G
Now
CAP MR
Rejected 
02/13/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
02/13/2025
02/20/2025
IV
2.25G
Q8 X7days
CAP
Waiting Final Action 
02/13/2025
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
02/13/2025
02/26/2025
TOPICAL
Apply Genorously
OD X7days
Burn Injury
Waiting Final Action 
02/22/2025
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
02/22/2025
02/28/2025
TOPICAL
Pea Size
Q12
Burn
Waiting Final Action 
02/25/2025
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
02/25/2025
03/03/2025
TOPICAL
Pea Size
Q12
Burn
Waiting Final Action 
03/02/2025
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
03/02/2025
03/09/2025
TOPICAL
3-5mm
BID
Burn
Waiting Final Action 
03/03/2025
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
03/03/2025
03/10/2025
TOPICAL
3-5mm
BID
Burn
Waiting Final Action 
03/03/2025
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
03/03/2025
03/03/2025
IV
500mg
OD
Pneumonia
Waiting Final Action 
03/03/2025
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
03/03/2025
03/10/2025
IV
250mg
OD
Pneumonia
Waiting Final Action 
03/03/2025
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
03/03/2025
03/10/2025
IV
500mg
Every 8hours
Anaerobic Infection
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: